 |
|
[Apha Biz=(Chicago) Reporter Paul Lee] Daewoong Pharmaceutical Co. said on the 3rd that it ranked No. 2 in the Korea Health Industry Development Institute's survey on overseas awareness of the Korean bio-health industry in 2022 in the pharmaceutical field and No. 1 among pharmaceutical companies.
The overseas awareness survey conducted by the Korea Health Industry Development Institute has been conducted annually since 2021 to identify the brand power and international competitiveness of the Korean bio-health industry and to derive customized strategies for each country when entering overseas markets. The survey, which marks its second anniversary this year, was conducted on 9,485 medical and industry experts and ordinary people from 19 major countries, including the U.S., China, Japan, the U.K., France and Germany, where domestic bio-health products are exported.
According to a survey of certain companies' awareness, Samsung BioLogics has the highest recognition in the pharmaceutical sector. However, Daewoong Pharmaceutical had the highest recognition among domestic pharmaceutical companies that export their own products.
Following Daewoong Pharmaceutical, ▲Hanmi Pharmaceutical (33.8%), ▲GC Green Cross (31.7%), and ▲Yuhan Corporation (26.0%) followed.
The company explained that Daewoong Pharmaceutical has shown the highest global recognition among Korean pharmaceutical companies because it has been investing heavily in research and development (R&D) over the past few decades and expanding its strides into overseas markets based on its own new drugs.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
